The company stated in a press release, “Aker believes krill supplement sales will soon become the second largest category of omega-3 supplements in [the food, drug, and mass channel]."
Sales of omega-3 krill oil grew 43% in the natural retail channel in the last year. Krill ingredients supplier Aker BioMarine Antarctic (Oslo, Norway) reported the statistic, which it obtained from market researcher SPINS*, at the recent SupplySide West trade show in October. It says krill oil’s growth outpaced the growth of other sources of omega-3s.
Aker BioMarine, which supplies Superba krill oil, said the skyrocketing growth likely stems from high interest in the food, drug, and mass channel, where krill supplement sales grew 70% last year. “At this rate,” the company stated in a press release, “Aker believes krill supplement sales will soon become the second largest category of omega-3 supplements in [the food, drug, and mass channel].”
“We are encouraged by these numbers because [they signify] reinvigorated growth in the natural channel,” said Aker’s vice president of global marketing Eric Anderson, in the press release. “A consumer study sponsored by Aker this year showed that nearly 4 out of 10 omega-3 supplement users are looking for an alternative omega-3 source.”
“Krill phospholipid omega-3s provide an excellent user experience in the form of smaller capsules and easy digestion, both of which continue to drive repeat purchase,” he added.
* SPINSscan Natural data from the 52 weeks ending July 7, 2012.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.